The next generation of groundbreaking weight loss drugs used by millions is just over the horizon - and they won't require ...

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of.  | The combined company is ...

Not all chronic pain is the same. Learn how to identify the type you have—and discover which treatments, including ...

Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient ...

Ligand Pharmaceuticals Incorporated ("Ligand”) (Nasdaq: LGND) and Channel Therapeutics Corporation ("Channel”) (NYSE American ...

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic ...

A first in human proof of concept phase I clinical study of VAS-101 (Vasceptor®; topical curcumin gel) in sickle cell disease (SCD) is underway. The study is being conducted by the Foundation for ...

Avicanna reported annual revenue of CA$25.5 million ($18.38 million) for the year ended December 31, 2024, up 52% compared to ...

Completion of Topical Gel Observational Real-World Evidence Study in Patients with Musculoskeletal Pain and Inflammation ...

ZYN002 is safe and effectively reduces irritability-related behavioral symptoms in children and adolescents with fragile X ...

Mumbai: Lyka Labs Limited has announced that it has been granted an Indian Patent for its proprietary product, Pregabalin Gel ...